読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$0.5897
+$0.0092 · +1.58%
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
前日終値
$0.5897
+$0.0092 · +1.58%
日中の時刻はETです。市場データは遅延する場合があります。
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
日中レンジ
現在 $0.5897
52週レンジ
現在 $0.5897
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
69
割安
センチメント
57
まちまち
リスク
66
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
日中レンジ
現在 $0.5897
52週レンジ
現在 $0.5897
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.08億 USD | 9004.9万 USD | 7019.3万 USD | 3705.4万 USD | 2223.9万 USD |
| 売上原価 | 4343.4万 USD | 3490.8万 USD | 2626.4万 USD | 1783.5万 USD | 1167.5万 USD |
| 粗利益 | 6444.1万 USD | 5514.1万 USD | 4392.9万 USD | 1921.9万 USD | 1056.4万 USD |
| 研究開発 | 1035万 USD | 1055.2万 USD | 637.6万 USD | 755.7万 USD | 558.9万 USD |
| 販売・一般管理 | 6675.1万 USD | 6139.6万 USD | 5992.5万 USD | 5012.1万 USD | 3021.7万 USD |
| 営業費用 | 7984.2万 USD | 7986.3万 USD | 7125.6万 USD | 5711.9万 USD | 3740.5万 USD |
| 受取利息 | 150.2万 USD | 107.8万 USD | 108.8万 USD | 12.5万 USD | 1.1万 USD |
| 支払利息 | 1216.1万 USD | 762.9万 USD | 577.2万 USD | 274.3万 USD | 187.5万 USD |
| 減価償却費と償却費 | 920.8万 USD | 803.9万 USD | 685.9万 USD | 490.9万 USD | 303.6万 USD |
| 営業利益 | −1540.1万 USD | −2472.2万 USD | −2732.7万 USD | −3790万 USD | −2684.1万 USD |
| 純利益 | −3351.9万 USD | −3806.9万 USD | −4310万 USD | −4404.4万 USD | −2900.2万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
